Pay in 4 interest-free payments of $6.67 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
We estimate that roughly half of people affected by obesity in the US will be eligible to benefit from GLP-1s overall, around 50 million people
Didnt have severe insulin resistance, metabolic syndrome, or diabetes before starting Realistic expectations
Eloralintide Novos delays and the strategy behind them Lillys surprising phase 2 results (up to 20% weight loss) Combination therapies with tirzepatide or retatrutide 22:30 FDA Pipeline Acceleration Potential removal of traditional phase 3 trials How this speeds up the arrival of next-generation therapies 24:15 Oral GLP-1 Small Molecules (Structure Therapeutics) Alaniglipron data and the stock surge Comparisons to orforglipron and past failures like denuglipron Why Dave remains skeptical 28:40 Sponsor Break: Shed & Shapa Access, coaching, and patient support Using a numberless scale to build a healthier relationship with weight tracking 31:10 Counterfeit Ozempic Warning New fake lot discovered in U.S
Some studies suggest that GIP may promote energy storage, while others indicate potential weight loss benefits, particularly when combined with GLP-1 agonism
US$ 29.10
US$ 21.88
US$ 25.18
US$ 20.39
US$ 24.51
